Discover and read the best of Twitter Threads about #GLP1
Most recents (2)
As it becomes better known and understood, #GLP1 will set a sharp bar for weight-loss coaches:
Semaglutide helps overweight and obese clients consistently (~60% of clients) lose and maintain 15% of their BW lost in 68 weeks (~16 months)
How will you beat that? 🧵
Semaglutide helps overweight and obese clients consistently (~60% of clients) lose and maintain 15% of their BW lost in 68 weeks (~16 months)
How will you beat that? 🧵
Maybe cost?
If weight loss is someone's priority and they have $1000 a month to spend, maybe the cost-benefit would favor you...
But can you deliver those consistent results?
Can you compete with prices in Poland?
Eventually, prices may fall... /1
If weight loss is someone's priority and they have $1000 a month to spend, maybe the cost-benefit would favor you...
But can you deliver those consistent results?
Can you compete with prices in Poland?
Eventually, prices may fall... /1
Maybe side-effects?
GLP-1 agonists have known and unknown side effects and interactions, and you might play up the anxiety/fear card (ew)...
But diets have side-effects, too. Hunger. Disordered eating. Social anxiety. Are you honest with clients about those possibilities? /2
GLP-1 agonists have known and unknown side effects and interactions, and you might play up the anxiety/fear card (ew)...
But diets have side-effects, too. Hunger. Disordered eating. Social anxiety. Are you honest with clients about those possibilities? /2
#Endocrinology #Endotwitter @RpratleyMD @ethanjweiss @parthaskar @SaifiTaban @AlbalawiZaina @drkevinfernando @drricardocorrea @CMichaelGibson @cpcannon @Sonia_ButaliaMD @mmamas1973 @SABOURETCardio FOLLOW us here for accredited programs at the speed of Twitter!
1) Welcome to a tweetorial on #insulinhesitancy in contemporary #T2D management. This serialized program is accredited for 0.5h by @academiccme: #physicians, #nurses, #pharmacists! I am @AliceYYCheng . . .
. . . and this educational activity is intended for healthcare providers and is supported by grants from AstraZeneca, Bayer, Chiesi, and NovoNordisk.
